"Disease mongering" claim as testosterone prescribing soars

Professor David Handelsman, director of the ANZAC Research Institute at the University of Sydney,  found total annual expenditure on testosterone products rose nine-fold over the past 20 years to $12.7 m a year, based on PBS data.

Spending had surged since 2006, driven by the introduction of two new testosterone products, a depot injectable testosterone and a transdermal testosterone gel, he said.

Increased prescribing could be not explained solely by increased diagnosis of Klinefelter syndrome but prescribing was likely increasing for non-approved